Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Body mass index between 18 and 32 kilograms/meter squared (kg/m\^2) inclusive, at the screening visit.
Healthy, as determined by physical examination, vital signs, electrocardiograms (ECGs), and clinical laboratory assessments (including hematology, chemistry, and urinalysis) within the normal range at the screening visit and/or on Day -1.
Cytochrome P450 (CYP) 2C19 normal, rapid, or ultrarapid metabolizer, as determined by genotyping during screening.
You may not be if
Any significant acute or chronic medical illness.
Current or history of clinically significant cardiac condition, including but not limited to arrhythmia, left ventricular systolic dysfunction, coronary heart disease; current, history, or family history of hypertrophic cardiomyopathy; or evidence of prior myocardial infarction based on ECGs.
CYP2C19 poor (\*2/\*2, \*3/\*3, or \*2/\*3) or intermediate (\*1/\*2, \*1/\*3, \*2/\*17) metabolizer, as determined by genotyping during screening.
Use of CYP2C19 and CYP3A4 inducers or inhibitors within 28 days of study intervention administration.
Clareo Health | A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
